ABBV-444
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye Syndrome
Conditions
Dry Eye Syndrome
Trial Timeline
Jun 27, 2023 → Oct 6, 2023
NCT ID
NCT05878067About ABBV-444
ABBV-444 is a phase 3 stage product being developed by AbbVie for Dry Eye Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05878067. Target conditions include Dry Eye Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05878067 | Phase 3 | Completed |
Competing Products
20 competing products in Dry Eye Syndrome